About BIOHIT HealthCare

About BIOHIT Healthcare Ltd

10-year anniversary BIOHIT HealthCare

Based in the North West of England, BIOHIT Healthcare Ltd is part of the Finnish public company, BIOHIT OYJ, which specialises in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases.

What we do

BIOHT HealthCare provides products and services for the prompt diagnosis of a range of gastrointestinal diseases, as well as tests for screening and monitoring disease progression.

"We believe that innovation is key to driving improvements and, through our academic and clinical relationships, we specialise in transferring successful research applications into routine clinical use"

Our products are categorised into three main groups:


  • Quick tests for endoscopy, clinics and point-of-care settings

  • Laboratory assays for supporting clinicians with a centralised service

  • Products for the elimination of carcinogenic acetaldehyde in the gastrointestinal tract 

Each category is enriched with innovation and class-leading products that really make a difference to clinical practice and patient management, while also reducing healthcare costs, improving patient outcomes and extending life.

Why we do it

The key objective of our business is to develop and deliver robust products that support the following:


  • Prevention of diseases of the gastrointestinal tract

  • Faster diagnosis of disease (at a more curable stage),

  • Effective monitoring of chronic diseases to support better management of the condition

  • Rapid and efficacious treatments

  • Development and commissioning of effective gastroenterology services including:

    • Better access to primary care diagnostics

    • Efficient referral strategies

    • Patient self-management​ and virtualisation of clinics

    • Engaging in goal-oriented clinical research

    • Supporting the development of guidelines

In the United Kingdom, diseases of the gastrointestinal tract - both functional and organic - constitute a significant proportion of a primary care physician's workload and, as such, the cost to both the NHS and the UK economy is huge. The economic impact of gastrointestinal disease was £7.18bn in 2004..

Estimated burden of gastrointestinal disorders:

  • Incidence of gastroesophageal reflux disease (GORD) 20-40 %

  • GP consultations for dyspepsia 1-4 %

  • Percentage of the total UK drug budget for dyspepsia 10 %

  • Incidence of irritable bowel syndrome (IBS) 10-22 %

  • Prevalence of coeliac disease 1 %

  • Prevalence of inflammatory bowel disease (IBD) 250,000

  • Annual percentage of population that undergoes endoscopy 1-2 %

  • Incidence of gastrointestinal cancers

    • Oesophageal 12 per 100,000​

    • Gastric 17 per 100,000

    • Colorectal 55 per 100,000

We have a core interest and focus in these disease areas.

How we do it

We are a leader in gastrointestinal diagnostics and use the expertise of our employees, advisers and partners to deliver safe and cost-effective products that meet universal clinical needs. 

Our research and development combines expertise in various fields into integrated knowhow. BIOHIT personnel, together with scientific advisers representing various academic communities, apply their knowledge in basic and applied research to develop innovative products for healthcare providers globally.

The key personnel are experts in the fields of:


  • Biotechnology

  • Biochemistry

  • Medicine

  • Molecular biology

  • Optics

This multidisciplinary approach has produced valuable results for the advancement of research in digestive healthcare all over the world, and our expertise enables us to react quickly to new customer needs and product ideas.


BIOHIT in brief

  • Established in 1988 by Prof. Osmo Suovaniemi

  • Develops safe and cost effective products for early detection and prevention of gastrointestinal diseases

  • Production in Finland


  • Operations based on long-term innovation and patenting strategy

  • Close collaboration with scientific communities

  • Technologies, products and services based on research results


and patents


BIOHIT group worldwide

  • Employs around 50 people

  • Headquartered in Helsinki

  • Subsidiaries in Italy and UK

  • Global distribution

  • Series B share (BIOBV) quoted on NASDAQ OMX Helsinki, Small cap  / healthcare since 1999

Our partners



Immundiagnostik AG is a company that specialises in the development of innovative parameters and detection methods for laboratory diagnostics and research applications.

BIOHIT HealthCare distributes products from Immundiagnostik AG in the UK and Ireland.


Preventis GmbH develops and manufactures cutting-edge rapid tests for diagnosis and monitoring of multiple diseases.

BIOHIT HealthCare distributes products from Preventis GmbH in the UK and Ireland

Genetic Analysis

Genetic Analysis AS develops and supplies CE-marked and standardised technology for gut microbiota analysis.

BIOHIT HealthCare distributes products and services from Genetic Analysis AS in the UK and Ireland.


RDBiomed Ltd developed and manufactures Peptest™ , a novel non-invasive diagnostic test for the detection and quantification of pepsin in saliva samples.

BIOHIT HealthCare distributes Peptest™ test kit and analytical service in the UK and Ireland.



BIOHIT products* are also available through our excellent distributor network. Select below to find your local distributor.

*Not all products are available in all areas. Please contact us or your local distributor for further info.

Box Delivery